FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324137063> ?p ?o ?g. }

• W4324137063 endingPage "137" @default.
• W4324137063 startingPage "137" @default.
• W4324137063 abstract "137 Background: Main approach for early biochemical relapse (BR) after radical prostatectomy (RP) is prostate bed salvage radiotherapy (SRT). PSICHE is a prospective trial aimed to explore oncological results of a 68Ga-PSMA-11 PET/CT tailored strategy based on a pre-defined treatment algorithm. We present results focusing on early biochemical outcomes after therapy. Biochemical response was defined as Complete (CBR) or Partial (PBR) if a PSA < 0.2 or <50% of baseline was reached. Methods: Enrolled patients were affected by BR (defined as PSA > 0.2 ng/ml) after RP +/- postoperative SRT. PSA >1 at recurrence or PSA persistence after surgery (PSA >0.2 ng within 16 weeks from RP) were exclusion criteria. All patients underwent centralized 68Ga-PSMA PET/CT and treatment approach was performed according to predefined criteria. Observation and re-staging at further PSA progression were proposed to patients with negative PSMA and previous postoperative RT. Prostate bed SRT was proposed to all patients with negative staging or positive imaging within the prostate bed. Stereotactic body radiotherapy (SBRT) to all sites of disease was proposed to patients with pelvic nodal recurrence (nodal disease <2 cm under aortic bifurcation) or oligometastatic disease (< 3 non visceral metastatic lesions). Non oligometastatic disease was treated with Androgen deprivation therapy +/- other systemic treatment. Results: Enrollment started on 19/03/2021 and 104 patients have been enrolled, with a median baseline PSA of 0.39 ng/ml. Overall, PSMA results were negative/positive in prostate bed in 75 patients (72.1%), while pelvic nodal or extrapelvic metastatic disease were detected in 23 (22.1%) and 6 (5.76%) patients, respectively. Twenty-two patients were observed after re-staging and were excluded from the current analysis. Treatment provided was SRT, SBRT or ADT in 50 (48.1%), 29 (27.8%) and 3 (2.9%) patients, respectively. Data about biochemical response at 3 months after treatment were available for 53 patients. Of these, 33 (62.3%) had a PBR, out of whom CBR was detected in 29 (54.7%). Any reduction in PSA if compared to baseline was detected in 44 patients, for an overall biochemical response rate of 83%. Five patients had biochemical progression and underwent a second PSMA re-staging with distant metastases detection. Only 2 patients experienced G2 Genitourinary toxicity, no G2 Gastrointestinal toxicity was recorded. Chi square test did not detect impact of ISUP score (< or >3) or time to recurrence (measured between surgery and biochemical relapse) on CBR rate. Conclusions: A PSMA targeted salvage treatment strategy offered promising results in terms of early biochemical response, with optimal toxicity profile, and avoided unnecessary overtreatment in this setting. Longer follow up is needed to explore biochemical relapse free and progression free survival after this approach. Clinical trial information: NCT05022914 ." @default.
• W4324137063 created "2023-03-15" @default.
• W4324137063 creator A5001236278 @default.
• W4324137063 creator A5004055773 @default.
• W4324137063 creator A5020557629 @default.
• W4324137063 creator A5028101803 @default.
• W4324137063 creator A5032174060 @default.
• W4324137063 creator A5039338924 @default.
• W4324137063 creator A5042589418 @default.
• W4324137063 creator A5048500404 @default.
• W4324137063 creator A5050509169 @default.
• W4324137063 creator A5053239100 @default.
• W4324137063 creator A5054019294 @default.
• W4324137063 creator A5059834254 @default.
• W4324137063 creator A5060114146 @default.
• W4324137063 creator A5061765305 @default.
• W4324137063 creator A5066539183 @default.
• W4324137063 creator A5071628142 @default.
• W4324137063 creator A5079718032 @default.
• W4324137063 creator A5082293852 @default.
• W4324137063 creator A5087468389 @default.
• W4324137063 creator A5089626999 @default.
• W4324137063 date "2023-02-20" @default.
• W4324137063 modified "2023-10-16" @default.
• W4324137063 title "Early biochemical outcomes following PSMA-guided approach for biochemical relapse after prostatectomy: PSICHE trial." @default.
• W4324137063 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.137" @default.
• W4324137063 hasPublicationYear "2023" @default.
• W4324137063 type Work @default.
• W4324137063 citedByCount "1" @default.
• W4324137063 countsByYear W43241370632023 @default.
• W4324137063 crossrefType "journal-article" @default.
• W4324137063 hasAuthorship W4324137063A5001236278 @default.
• W4324137063 hasAuthorship W4324137063A5004055773 @default.
• W4324137063 hasAuthorship W4324137063A5020557629 @default.
• W4324137063 hasAuthorship W4324137063A5028101803 @default.
• W4324137063 hasAuthorship W4324137063A5032174060 @default.
• W4324137063 hasAuthorship W4324137063A5039338924 @default.
• W4324137063 hasAuthorship W4324137063A5042589418 @default.
• W4324137063 hasAuthorship W4324137063A5048500404 @default.
• W4324137063 hasAuthorship W4324137063A5050509169 @default.
• W4324137063 hasAuthorship W4324137063A5053239100 @default.
• W4324137063 hasAuthorship W4324137063A5054019294 @default.
• W4324137063 hasAuthorship W4324137063A5059834254 @default.
• W4324137063 hasAuthorship W4324137063A5060114146 @default.
• W4324137063 hasAuthorship W4324137063A5061765305 @default.
• W4324137063 hasAuthorship W4324137063A5066539183 @default.
• W4324137063 hasAuthorship W4324137063A5071628142 @default.
• W4324137063 hasAuthorship W4324137063A5079718032 @default.
• W4324137063 hasAuthorship W4324137063A5082293852 @default.
• W4324137063 hasAuthorship W4324137063A5087468389 @default.
• W4324137063 hasAuthorship W4324137063A5089626999 @default.
• W4324137063 hasConcept C121608353 @default.
• W4324137063 hasConcept C126322002 @default.
• W4324137063 hasConcept C126838900 @default.
• W4324137063 hasConcept C126894567 @default.
• W4324137063 hasConcept C141071460 @default.
• W4324137063 hasConcept C143998085 @default.
• W4324137063 hasConcept C2776235491 @default.
• W4324137063 hasConcept C2777008409 @default.
• W4324137063 hasConcept C2777899217 @default.
• W4324137063 hasConcept C2779466945 @default.
• W4324137063 hasConcept C2780192828 @default.
• W4324137063 hasConcept C509974204 @default.
• W4324137063 hasConcept C71924100 @default.
• W4324137063 hasConceptScore W4324137063C121608353 @default.
• W4324137063 hasConceptScore W4324137063C126322002 @default.
• W4324137063 hasConceptScore W4324137063C126838900 @default.
• W4324137063 hasConceptScore W4324137063C126894567 @default.
• W4324137063 hasConceptScore W4324137063C141071460 @default.
• W4324137063 hasConceptScore W4324137063C143998085 @default.
• W4324137063 hasConceptScore W4324137063C2776235491 @default.
• W4324137063 hasConceptScore W4324137063C2777008409 @default.
• W4324137063 hasConceptScore W4324137063C2777899217 @default.
• W4324137063 hasConceptScore W4324137063C2779466945 @default.
• W4324137063 hasConceptScore W4324137063C2780192828 @default.
• W4324137063 hasConceptScore W4324137063C509974204 @default.
• W4324137063 hasConceptScore W4324137063C71924100 @default.
• W4324137063 hasIssue "6_suppl" @default.
• W4324137063 hasLocation W43241370631 @default.
• W4324137063 hasOpenAccess W4324137063 @default.
• W4324137063 hasPrimaryLocation W43241370631 @default.
• W4324137063 hasRelatedWork W1515906819 @default.
• W4324137063 hasRelatedWork W1979955543 @default.
• W4324137063 hasRelatedWork W1998796379 @default.
• W4324137063 hasRelatedWork W2042143271 @default.
• W4324137063 hasRelatedWork W2116884624 @default.
• W4324137063 hasRelatedWork W2192988598 @default.
• W4324137063 hasRelatedWork W2472951163 @default.
• W4324137063 hasRelatedWork W2598486776 @default.
• W4324137063 hasRelatedWork W3038030631 @default.
• W4324137063 hasRelatedWork W4319748405 @default.
• W4324137063 hasVolume "41" @default.
• W4324137063 isParatext "false" @default.
• W4324137063 isRetracted "false" @default.
• W4324137063 workType "article" @default.